The clinical trial is not yet open for recruitment, and it isn’t clear from the posting where recruitment will occur. The new biologic is identified as AMG 557/MEDI5872 and produced by Amgen and AstraZeneca. The drug already completed a Phase 1 trial for SLE (lupus). From the Amgen site:
AMG 557 is a human monoclonal antibody that inhibits the action of B7 related protein (B7RP-1). It is being investigated as a treatment for systemic lupus erythematosus. AMG 557 is being jointly developed in collaboration with AstraZeneca Plc.
Considering the similarities between SLE and SS, I would expect to see more drugs being tested for both SLE and SS at the same time. With a phase 2 trial that has not yet started, it will be years before SS patients have an approved drug, but it’s always nice to widen the pipeline.